Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?

• Nicola M
• Alsafi Z
• Sohrabi C
• et al.

The socio-economic implications of the coronavirus pandemic (COVID-19): a review.

Int J Surg. 2020; 78: 185-193

• Baden LR
• El Sahly HM
• Essink B
• et al.

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.

N Engl J Med. 2021; 384: 403-416

• Polack FP
• Thomas SJ
• Kitchin N
• et al.

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

N Engl J Med. 2020; 383: 2603-2615

• Logunov DY
• Dolzhikova IV
• Shcheblyakov DV
• et al.

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.

Lancet. 2021; 397: 671-681

• Fontanet A
• Autran B
• Lina B
• Kieny MP
• Karim SSA
• Sridhar D

SARS-CoV-2 variants and ending the COVID-19 pandemic.

Lancet. 2021; 397: 952-954

• Tillett RL
• Sevinsky JR
• Hartley PD
• et al.

Genomic evidence for reinfection with SARS-CoV-2: a case study.

Lancet Infect Dis. 2021; 21: 52-58

• To KK-W
• Hung IF-N
• Ip JD
• et al.

Coronavirus disease 2019 (COVID-19) re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain confirmed by whole genome sequencing.

Clin Infect Dis. 2020; ()

• Van Elslande J
• Vermeersch P
• Vandervoort K
• et al.

Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain.

Clin Infect Dis. 2021; 73: 354-356

• Gupta V
• Bhoyar RC
• Jain A
• et al.

Asymptomatic reinfection in 2 healthcare workers from India with genetically distinct severe acute respiratory syndrome coronavirus 2.

Clin Infect Dis. 2020; ()

Understanding protection from SARS-CoV-2 by studying reinfection.

Nat Med. 2020; 26: 1680-1681

• Prado-Vivar B
• Becerra-Wong M
• Guadalupe JJ
• et al.

COVID-19 re-infection by a phylogenetically distinct SARS-CoV-2 variant, first confirmed event in South America.

SSRN Electron J. 2020; ()

• Tomassini S
• Kotecha D
• Bird PW
• Folwell A
• Biju S
• Tang JW

Setting the criteria for SARS-CoV-2 reinfection – six possible cases.

J Infect. 2020; 82 (): 282

• Harrington D
• Kele B
• Pereira S
• et al.

Confirmed reinfection with SARS-CoV-2 variant VOC-202012/01.

Clin Infect Dis. 2021; ()

• Zhang J
• Ding N
• Ren L
• et al.

COVID-19 reinfection in the presence of neutralizing antibodies.

Natl Sci Rev. 2021; 8nwab006

• Hall V
• Foulkes S
• Charlett A
• et al.

Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England: June to November 2020.

medRxiv. 2021; ()

• Lumley SF
• O’Donnell D
• Stoesser NE
• et al.

Antibody status and incidence of SARS-CoV-2 infection in health care workers.

N Engl J Med. 2021; 384: 533-540

• Harvey RA
• Rassen JA
• Kabelac CA
• et al.

Association of SARS-CoV-2 seropositive antibody test with risk of future infection.

JAMA Intern Med. 2021; 181: 672-679

• Abu-Raddada LJ
• Chemaitelly H
• Coyle P
• et al.

SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy.

EClinicalMedicine. 2021; 35100861

• Hansen CH
• Michlmayr D
• Gubbels SM
• Mølbak K
• Ethelberg S

Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study.

Lancet. 2021; 397: 1204-1212

• Liang Y
• Wang ML
• Chien CS
• et al.

Highlight of immune pathogenic response and hematopathologic effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 infection.

Front Immunol. 2020; 111022

• Ye ZW
• Yuan S
• Yuen KS
• Fung SY
• Chan CP
• Jin DY

Zoonotic origins of human coronaviruses.

Int J Biol Sci. 2020; 16: 1686-1697

• Hoffmann M
• Kleine-Weber H
• Schroeder S
• et al.

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.

Cell. 2020; 181 (): 271

MDA5 Governs the innate immune response to SARS-CoV-2 in lung epithelial cells.

Cell Rep. 2021; 34108628

Evasion of type I interferon by SARS-CoV-2.

Cell Rep. 2020; 33108234

• Zheng Y
• Zhuang MW
• Han L
• et al.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling.

Signal Transduct Target Ther. 2020; 5: 299

Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation.

Science. 2015; 347aaa2630

• Tang F
• Quan Y
• Xin Z-T
• et al.

Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study.

J Immunol. 2011; 186: 7264-7268

• Wu LP
• Wang NC
• Chang YH
• et al.

Duration of antibody responses after severe acute respiratory syndrome.

Emerg Infect Dis. 2007; 13: 1562-1564

• Woo PCY
• Lau SKP
• Wong BHL
• et al.

Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus.

Clin Diagn Lab Immunol. 2004; 11: 665-668

• Temperton NJ
• Chan PK
• Simmons G
• et al.

Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes.

Emerg Infect Dis. 2005; 11: 411-416

• Guo X
• Guo Z
• Duan C
• et al.

Long-Term Persistence of IgG Antibodies in SARS-CoV Infected Healthcare Workers.

medRxiv. 2020; ()

• Alshukairi AN
• Khalid I
• Ahmed WA
• et al.

Antibody response and disease severity in healthcare worker MERS survivors.

Emerg Infect Dis. 2016; 22: 1113-1115

• Payne DC
• Iblan I
• Rha B
• et al.

Persistence of antibodies against middle east respiratory syndrome coronavirus.

Emerg Infect Dis. 2016; 22: 1824-1826

• Houser KV
• Broadbent AJ
• Gretebeck L
• et al.

Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody.

PLoS Pathog. 2017; 13e1006565

• Siggins MK
• Thwaites RS
• Openshaw PJM

Durability of immunity to SARS-CoV-2 and other respiratory viruses.

Trends Microbiol. 2021; 29: 648-662

Direct observation of repeated infections with endemic coronaviruses.

J Infect Dis. 2021; 223: 409-415

• Edridge AWD
• Kaczorowska J
• Hoste ACR
• et al.

Seasonal coronavirus protective immunity is short-lasting.

Nat Med. 2020; 26: 1691-1693

• Hall CB
• Walsh EE
• Long CE
• Schnabel KC

Immunity to and frequency of reinfection with respiratory syncytial virus.

J Infect Dis. 1991; 163: 693-698

• Glezen WP
• Taber LH
• Frank AL
• Kasel JA

Risk of primary infection and reinfection with respiratory syncytial virus.

Am J Dis Child. 1986; 140: 543-546

• Addetia A
• Crawford KHD
• Dingens A
• et al.

Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate.

J Clin Microbiol. 2020; 58: e02107-e02120

COVID-19 human challenge studies in the UK.

Lancet Respir Med. 2020; 8: e96

First volunteers on COVID-19 human challenge study leave quarantine.

Imperial College London,
March 25, 2021

• Hassan AO
• Case JB
• Winkler ES
• et al.

A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies.

Cell. 2020; 182 (): 744

• Imai M
• Iwatsuki-Horimoto K
• Hatta M
• et al.

Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development.

Proc Natl Acad Sci USA. 2020; 117: 16587-16595

• Rogers TF
• Zhao F
• Huang D
• et al.

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.

Science. 2020; 369: 956-963

• Ryan KA
• Bewley KR
• Fotheringham SA
• et al.

Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity.

Nat Commun. 2021; 12: 81

• Chandrashekar A
• Liu J
• Martino AJ
• et al.

SARS-CoV-2 infection protects against rechallenge in rhesus macaques.

Science. 2020; 369: 812-817

• Ni L
• Ye F
• Cheng M-L
• et al.

Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals.

Immunity. 2020; 52 (): 971

• Wheatley AK
• Juno JA
• Wang JJ
• et al.

Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19.

Nat Commun. 2021; 121162

• Chia WN
• Zhu F
• Ong SWX
• et al.

Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study.

Lancet Microbe. 2021; 2: e240-e249

• Röltgen K
• Powell AE
• Wirz OF
• et al.

Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome.

Sci Immunol. 2020; 5eabe0240

Not just antibodies: B cells and T cells mediate immunity to COVID-19.

Nat Rev Immunol. 2020; 20: 581-582

• Premkumar L
• Segovia-Chumbez B
• Jadi R
• et al.

The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients.

Sci Immunol. 2020; 5eabc8413

• Zost SJ
• Gilchuk P
• Chen RE
• et al.

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein.

Nat Med. 2020; 26: 1422-1427

• Iyer AS
• Jones FK
• Nodoushani A
• et al.

Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients.

Sci Immunol. 2020; 5eabe0367

• Wang P
• Liu L
• Nair MS
• et al.

SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease.

Emerg Microbes Infect. 2020; 9: 2091-2093

• Crawford KHD
• Dingens AS
• Eguia R
• et al.

Dynamics of neutralizing antibody titers in the months after severe acute respiratory syndrome coronavirus 2 infection.

J Infect Dis. 2021; 223: 197-205

• Legros V
• Denolly S
• Vogrig M
• et al.

A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity.

Cell Mol Immunol. 2021; 18: 318-327

• Seow J
• Graham C
• Merrick B
• et al.

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans.

Nat Microbiol. 2020; 5: 1598-1607

• Zhang Y
• Zhang J
• Chen Y
• et al.

The ORF8 protein of SARS-CoV-2 mediates immune evasion through potently downregulating MHC-I.

bioRxiv. 2020; ()

• Hassan SS
• Aljabali AAA
• Panda PK
• et al.

A unique view of SARS-CoV-2 through the lens of ORF8 protein.

Comput Biol Med. 2021; 133104380

• Flower TG
• Buffalo CZ
• Hooy RM
• Allaire M
• Ren X
• Hurley JH

Structure of SARS-CoV-2 ORF8, a rapidly evolving immune evasion protein.

Proc Natl Acad Sci USA. 2021; 118e2021785118

• Harris RJ
• Whitaker HJ
• Andrews NJ
• et al.

Serological surveillance of SARS-CoV-2: six-month trends and antibody response in a cohort of public health workers.

J Infect. 2021; 82: 162-169

• Yao L
• Wang G-L
• Shen Y
• et al.

Persistence of antibody and cellular immune responses in COVID-19 patients over nine months after infection.

J Infect Dis. 2021; 224: 586-594

• Dispinseri S
• Secchi M
• Pirillo MF
• et al.

Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival.

Nat Commun. 2021; 122670

• Lau EHY
• Tsang OTY
• Hui DSC
• et al.

Neutralizing antibody titres in SARS-CoV-2 infections.

Nat Commun. 2021; 12: 63

• Sherina N
• Piralla A
• Du L
• et al.

Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6–8 months after the infection.

Med (N Y). 2021; 2 (): 281

Profile of specific antibodies to SARS-CoV-2: the first report.

J Infect. 2020; 81: 147-178

• Sterlin D
• Mathian A
• Miyara M
• et al.

IgA dominates the early neutralizing antibody response to SARS-CoV-2.

Sci Transl Med. 2021; 13eabd2223

• Manisty C
• Treibel TA
• Jensen M
• et al.

Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARSCoV-2 infection.

EBioMedicine. 2021; 65103259

• Yamayoshi S
• Yasuhara A
• Ito M
• et al.

Antibody titers against SARS-CoV-2 decline, but do not disappear for several months.

EClinicalMedicine. 2021; 32100734

• Rodda LB
• Netland J
• Shehata L
• et al.

Functional SARS-CoV-2-specific immune memory persists after mild COVID-19.

Cell. 2021; 184 (): 169

• Wajnberg A
• Amanat F
• Firpo A
• et al.

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.

Science. 2020; 370: 1227-1230

Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections.

Allergy. 2021; 76: 551-561

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications.

medRxiv. 2020; ()

• Long QX
• Tang XJ
• Shi QL
• et al.

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.

Nat Med. 2020; 26: 1200-1204

• Sakharkar M
• Rappazzo CG
• Wieland-Alter WF
• et al.

Prolonged evolution of the human B cell response to SARS-CoV-2 infection.

Sci Immunol. 2021; 6eabg6916

• Abayasingam A
• Balachandran H
• Agapiou D
• et al.

Long-term persistence of RBD⁺ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection.

Cell Rep Med. 2021; 2100228

• Vaisman-Mentesh A
• Dror Y
• Tur-Kaspa R
• et al.

SARS-CoV-2 specific memory B cells frequency in recovered patient remains stable while antibodies decay over time.

medRxiv. 2020; ()

• Gaebler C
• Wang Z
• Lorenzi JCC
• et al.

Evolution of antibody immunity to SARS-CoV-2.

Nature. 2021; 591: 639-644

• Dan JM
• Mateus J
• Kato Y
• et al.

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.

Science. 2021; 371eabf4063

• Newell KL
• Clemmer DC
• Cox JB
• et al.

Switched and unswitched memory B cells detected during SARS-CoV-2 convalescence correlate with limited symptom duration.

PLoS One. 2021; 16e0244855

• Oliviero B
• Varchetta S
• Mele D
• et al.

Expansion of atypical memory B cells is a prominent feature of COVID-19.

Cell Mol Immunol. 2020; 17: 1101-1103

• Memoli MJ
• Han A
• Walters K-A
• et al.

Influenza A reinfection in sequential human challenge: implications for protective immunity and “universal” vaccine development.

Clin Infect Dis. 2020; 70: 748-753

• Saris A
• Reijnders TD
• Nossent EJ
• et al.

Distinct cellular immune profiles in the airways and blood of critically ill patients with COVID-19.

Thorax. 2021; 76: 1010-1019

• Wildner NH
• Ahmadi P
• Schulte S
• et al.

B cell analysis in SARS-CoV-2 versus malaria: Increased frequencies of plasmablasts and atypical memory B cells in COVID-19.

J Leukoc Biol. 2021; 109: 77-90

• Dugan H
• Stamper C
• Li L
• et al.

Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets.

Immunity. 2021; 54 (): 1290

• Zhao J
• Zhao J
• Mangalam AK
• et al.

Airway memory CD4(+) T cells mediate protective immunity against emerging respiratory coronaviruses.

Immunity. 2016; 44: 1379-1391

T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice.

J Virol. 2010; 84: 9318-9325

• Channappanavar R
• Fett C
• Zhao J
• Meyerholz DK
• Perlman S

Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection.

J Virol. 2014; 88: 11034-11044

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients.

EBioMedicine. 2020; 55102763

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages.

Nat Rev Immunol. 2020; 20: 355-362

COVID-19: immunopathology and its implications for therapy.

Nat Rev Immunol. 2020; 20: 269-270

• Liao M
• Liu Y
• Yuan J
• et al.

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19.

Nat Med. 2020; 26: 842-844

• Swain SL
• McKinstry KK
• Strutt TM

Expanding roles for CD4+ T cells in immunity to viruses.

Nat Rev Immunol. 2012; 12: 136-148

CD8(+) T cells: foot soldiers of the immune system.

Immunity. 2011; 35: 161-168

Adaptive immunity to SARS-CoV-2 and COVID-19.

Cell. 2021; 184: 861-880

• Grifoni A
• Weiskopf D
• Ramirez SI
• et al.

Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals.

Cell. 2020; 181 (): 1489

• Tarke A
• Sidney J
• Kidd CK
• et al.

Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases.

Cell Rep Med. 2021; 2100204

• Rydyznski Moderbacher C
• Ramirez SI
• Dan JM
• et al.

Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity.

Cell. 2020; 183: 996-1012.e19

• Weiskopf D
• Schmitz KS
• Raadsen MP
• et al.

Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome.

Sci Immunol. 2020; 5eabd2071

• Sekine T
• Perez-Potti A
• Rivera-Ballesteros O
• et al.

Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19.

Cell. 2020; 183 (): 158

• Schwarzkopf S
• Krawczyk A
• Knop D
• et al.

Cellular immunity in COVID-19 convalescents with PCR-confirmed infection but with undetectable SARS-CoV-2-specific IgG.

Emerg Infect Dis. 2021; 27: 122-129

• Luo M
• Liu J
• Jiang W
• Yue S
• Liu H
• Wei S

IL-6 and CD8+ T cell counts combined are an early predictor of in-hospital mortality of patients with COVID-19.

JCI Insight. 2020; 5e139024

• Tan AT
• Linster M
• Tan CW
• et al.

Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients.

Cell Rep. 2021; 34108728

• Diao B
• Wang C
• Tan Y
• et al.

Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19).

Front Immunol. 2020; 11: 827

Characteristics of SARS-CoV-2 and COVID-19.

Nat Rev Microbiol. 2020; 19: 141-154

• Le Bert N
• Tan AT
• Kunasegaran K
• et al.

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.

Nature. 2020; 584: 457-462

• Sridhar S
• Begom S
• Bermingham A
• et al.

Cellular immune correlates of protection against symptomatic pandemic influenza.

Nat Med. 2013; 19: 1305-1312

T follicular helper cells in germinal center B cell selection and lymphomagenesis.

Immunol Rev. 2020; 296: 48-61

• Juno JA
• Tan HX
• Lee WS
• et al.

Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19.

Nat Med. 2020; 26: 1428-1434

• Babiker A
• Marvil CE
• Waggoner JJ
• Collins MH
• Piantadosi A

The importance and challenges of identifying SARS-CoV-2 reinfections.

J Clin Microbiol. 2021; 59 (): e02769

• Mallett S
• Allen AJ
• Graziadio S
• et al.

At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data.

BMC Med. 2020; 18: 346

• Sethuraman N
• Jeremiah SS
• Ryo A

Interpreting diagnostic tests for SARS-CoV-2.

JAMA. 2020; 323: 2249-2251

• Ringlander J
• Nilsson S
• Westin J
• Lindh M
• Martner A
• Hellstrand K

Low incidence of reinfection with endemic coronaviruses diagnosed by real-time PCR.

J Infect Dis. 2021; 223: 2013-2014

Case fatality ratio of pandemic influenza.

Lancet Infect Dis. 2010; 10: 443-444

• Petersen E
• Koopmans M
• Go U
• et al.

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics.

Lancet Infect Dis. 2020; 20: e238-e244

• Nair H
• Nokes DJ
• Gessner BD
• et al.

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis.

Lancet. 2010; 375: 1545-1555

Epidemiology, genetic recombination, and pathogenesis of coronaviruses.

Trends Microbiol. 2016; 24: 490-502

Variation in frequency of natural reinfection with influenza A viruses.

J Med Virol. 1983; 12: 17-23

• Ng S
• Nachbagauer R
• Balmaseda A
• et al.

Novel correlates of protection against pandemic H1N1 influenza A virus infection.

Nat Med. 2019; 25: 962-967

• Wang J
• Zhuang G
• Jiang L
• Xu Y
• Ning C

Epidemiology of influenza virus reinfection: a retrospective analysis of a nine-year influenza surveillance data.

Res Sq. 2020; ()

• Hoffmann M
• Arora P
• Groß R
• et al.

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.

Cell. 2021; 184 (): 2384

• Garcia-Beltran WF
• Lam EC
• St Denis K
• et al.

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.

Cell. 2021; 184 (): 2372

• Abu-Raddad LJ
• Chemaitelly H
• Butt AA
• National Study Group for COVID-19 Vaccination

Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants.

N Engl J Med. 2021; 385: 187-189

• Hoffmann M
• Hofmann-Winkler H
• Krüger N
• et al.

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination.

Cell Rep. 2021; 36109415

• Ferreira I
• Datir R
• Papa G
• et al.

SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies.

bioRxiv. 2021; ()

• Planas D
• Veyer D
• Baidaliuk A
• et al.

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.

Nature. 2021; 596: 276-280

• Folegatti PM
• Ewer KJ
• Aley PK
• et al.

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

Lancet. 2020; 396: 467-478

• Earle KA
• Ambrosino DM
• Fiore-Gartland A
• et al.

Evidence for antibody as a protective correlate for COVID-19 vaccines.

Vaccine. 2021; 39: 4423-4428

• Sadarangani M
• Marchant A
• Kollmann TR

Immunological mechanisms of vaccine-induced protection against COVID-19 in humans.

Nat Rev Immunol. 2021; 21: 475-484

• Feldmann H
• Feldmann F
• Marzi A

Ebola: lessons on vaccine development.

Annu Rev Microbiol. 2018; 72: 423-446

• Bliss CM
• Bowyer G
• Anagnostou NA
• et al.

Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP.

Sci Rep. 2018; 83390

• Ramasamy MN
• Minassian AM
• Ewer KJ
• et al.

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

Lancet. 2021; 396: 1979-1993

• Lopez Bernal J
• Andrews N
• Gower C
• et al.

Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant.

N Engl J Med. 2021; 385: 585-594

• Sahin U
• Muik A
• Vogler I
• et al.

BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans.

medRxiv. 2020; ()

• Anderson EJ
• Rouphael NG
• Widge AT
• et al.

Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults.

N Engl J Med. 2020; 383: 2427-2438

• Spencer AJ
• McKay PF
• Belij-Rammerstorfer S
• et al.

Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice.

Nat Commun. 2021; 122893

• Nadesalingam A
• Cantoni D
• Wells DA
• et al.

Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK.

Lancet Microbe. 2021; 2: e416-e418

• Haas EJ
• Angulo FJ
• McLaughlin JM
• et al.

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.

Lancet. 2021; 397: 1819-1829

• Mor V
• Gutman R
• Yang X
• et al.

Short-term impact of nursing home SARS-CoV-2 vaccinations on new infections, hospitalizations, and deaths.

J Am Geriatr Soc. 2021; 69: 2063-2069

Correlates of protection from SARS-CoV-2 infection.

Lancet. 2021; 397: 1421-1423

• Koch T
• Mellinghoff SC
• Shamsrizi P
• Addo MM
• Dahlke C

Correlates of vaccine-induced protection against SARS-CoV-2.

Vaccines (Basel). 2021; 9: 238

• Angyal A
• Longet S
• Moore S
• et al.

T-cell and antibody responses to first BNT162b2 vaccine dose in previously SARS-CoV-2-infected and infection-naive UK healthcare workers: a multicentre, prospective, observational cohort study.

SSRN Electron J. 2021; ()

• Ebinger JE
• Fert-Bober J
• Printsev I
• et al.

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.

Nat Med. 2021; 27: 981-984

• Bolotin S
• Hughes SL
• Gul N
• et al.

What is the evidence to support a correlate of protection for measles? A systematic review.

J Infect Dis. 2020; 221: 1576-1583

• Altmann DM
• Boyton RJ
• Beale R

Immunity to SARS-CoV-2 variants of concern.

Science. 2021; 371: 1103-1104

• Madhi SA
• Baillie V
• Cutland CL
• et al.

Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant.

N Engl J Med. 2021; 384: 1885-1898

Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 trial.

• Emary KRW
• Golubchik T
• Aley PK
• et al.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.

Lancet. 2021; 397: 1351-1362

Novavax offers first evidence that COVID vaccines protect people against variants.

Nature. 2021; 590: 17

• Khoury DS
• Cromer D
• Reynaldi A
• et al.

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.

Nat Med. 2021; 27: 1205-1211

• Goel RR
• Apostolidis SA
• Painter MM
• et al.

Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination.

Sci Immunol. 2021; 6eabi6950

• Sadoff J
• Gray G
• Vandebosch A
• et al.

Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19.

N Engl J Med. 2021; 384: 2187-2201

• Rovida F
• Cassaniti I
• Paolucci S
• et al.

SARS-CoV-2 vaccine breakthrough infections are asymptomatic or mildly symptomatic and are infrequently transmitted.

medRxiv. 2021; ()

• Wang P
• Nair MS
• Liu L
• et al.

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.

Nature. 2021; 593: 130-135

• Starr TN
• Greaney AJ
• Hilton SK
• et al.

Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding.

Cell. 2020; 182 (): 1295

• Geers D
• Shamier MC
• Bogers S
• et al.

SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees.

Sci Immunol. 2021; 6eabj1750

• Tarke A
• Sidney J
• Methot N
• et al.

Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals.

Cell Rep Med. 2021; 2100355

• Redd AD
• Nardin A
• Kared H
• et al.

CD8+ T-cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants.

Open Forum Infect Dis. 2021; 8ofab143

• Cele S
• Gazy I
• Jackson L
• et al.

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.

Nature. 2021; 593: 142-146

• Wang Z
• Schmidt F
• Weisblum Y
• et al.

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.

Nature. 2021; 592: 616-622

• Chen RE
• Zhang X
• Case JB
• et al.

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.

Nat Med. 2021; 27: 717-726

• Skelly DT
• Harding AC
• Gilbert-Jaramillo J
• et al.

Vaccine-induced immunity provides more robust heterotypic immunity than natural infection to emerging SARS-CoV-2 variants of concern.

Res Sq. 2021; ()

• Muik A
• Wallisch A-K
• Sänger B
• et al.

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera.

Science. 2021; 371: 1152-1153

• Hacisuleyman E
• Hale C
• Saito Y
• et al.

Vaccine breakthrough infections with SARS-CoV-2 variants.

N Engl J Med. 2021; 384: 2212-2218

• Kustin T
• Harel N
• Finkel U
• et al.

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals.

Nat Med. 2021; 27: 1379-1384

• Brinkley-Rubinstein L
• Peterson M
• Martin R
• Chan P
• Berk J

Breakthrough SARS-CoV-2 infections in prison after vaccination.

N Engl J Med. 2021; 385: 1051-1052

• Rana K
• Mohindra R
• Pinnaka L

Vaccine breakthrough infections with SARS-CoV-2 variants.

N Engl J Med. 2021; 385: e7

• Jo WK
• Drosten C
• Drexler JF

The evolutionary dynamics of endemic human coronaviruses.

Virus Evol. 2021; 7veab020

• D’Amico F
• Rabaud C
• Peyrin-Biroulet L
• Danese S

SARS-CoV-2 vaccination in IBD: more pros than cons.

Nat Rev Gastroenterol Hepatol. 2021; 18: 211-213

• Cobey S
• Larremore DB
• Grad YH
• Lipsitch M

Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination.

Nat Rev Immunol. 2021; 21: 330-335

Covid-19: Millions could be offered booster vaccinations from September.

BMJ. 2021; 374n1686

Covid-19 booster vaccines: what we know and who’s doing what.

BMJ. 2021; 374n2082

• Levine-Tiefenbrun M
• Yelin I
• Alapi H
• et al.

Viral loads of delta-variant SARS-CoV2 breakthrough infections following vaccination and booster with the BNT162b2 vaccine.

medRxiv. 2021; ()

• Falsey AR
• Frenck Jr, RW
• Walsh EE
• et al.

SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3.

N Engl J Med. 2021; ()

• The Lancet Infectious Diseases

COVID-19 vaccine equity and booster doses.

Lancet Infect Dis. 2021; 211193

• Agrawal U
• Katikireddi SV
• McCowan C
• et al.

COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study.

Lancet Respir Med. 2021; ()

• Tartof SY
• Slezak JM
• Fischer H
• et al.

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.

Lancet. 2021; 398: 1407-1416

• Antonelli M
• Penfold RS
• Merino J
• et al.

Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.

Lancet Infect Dis. 2021; ()

• Kissler SM
• Tedijanto C
• Goldstein E
• Grad YH
• Lipsitch M

Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period.

Science. 2020; 368: 860-868